Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JANEX-1 |
Synonyms | |
Therapy Description |
JANEX-1 (WHI-P131) is a dual JAK3/EGFR inhibitor, which may prevent the development of intestinal tumors (PMID: 20924972, PMID: 20486473, PMID: 29026328). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JANEX-1 | WHI-P131 | EGFR Inhibitor (Pan) 62 JAK3 Inhibitor - ATP competitive 4 | JANEX-1 (WHI-P131) is a dual JAK3/EGFR inhibitor, which may prevent the development of intestinal tumors (PMID: 20924972, PMID: 20486473, PMID: 29026328). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK3 I87T | Advanced Solid Tumor | sensitive | JANEX-1 | Preclinical - Cell culture | Actionable | In a preclinical study, JANEX-1 (WHI-P131) inhibited proliferation of transformed cells expressing JAK3 I87T in culture (PMID: 18397343). | 18397343 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|